Terms: = Lung cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
3426 results:
1. Patient-derived tumoroids and proteomic signatures: tools for early drug discovery.
Lê H; Deforges J; Cutolo P; Lamarque A; Hua G; Lindner V; Jain S; Balloul JM; Benkirane-Jessel N; Quéméneur E
Front Immunol; 2024; 15():1379613. PubMed ID: 38698850
[TBL] [Abstract] [Full Text] [Related]
2. The relative risk of immune checkpoint inhibitor pneumonitis in advanced non-small- cell lung cancer: Meta-analyses of controlled clinical trials.
Kong Y; Hong L; Xu XC; Chen YF; Xu J
PLoS One; 2024; 19(4):e0301931. PubMed ID: 38683829
[TBL] [Abstract] [Full Text] [Related]
3. Molecular Diagnostics and treatment Patterns in Metastatic Non-small Cell lung cancer Patients: Real World Evidence from Greece: LACHESIS Study.
Charpidou A; Mani M; Kokkotou E; Stournara L; Stathelou L; Antoniadou K; Argyropoulos E; Syrigos KN
Anticancer Res; 2024 May; 44(5):2063-2072. PubMed ID: 38677737
[TBL] [Abstract] [Full Text] [Related]
4. Prediction of Responsiveness to pd-l1/PD-1 Inhibitors Using miRNA Profiles Associated With pd-l1 Expression in lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract] [Full Text] [Related]
5. Non-Small Cell lung cancer Metastatic Without Oncogenic Alterations.
Frost N; Reck M
Am Soc Clin Oncol Educ Book; 2024 Jun; 44(3):e432524. PubMed ID: 38669613
[TBL] [Abstract] [Full Text] [Related]
6. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
7. Risk Factors Analysis of AKI in Patients with Primary Non-small Cell lung cancer Treated with PD-1/pd-l1 Inhibitor.
Ying JM; Yan F
Iran J Kidney Dis; 2024 Mar; 18(2):108-117. PubMed ID: 38660695
[TBL] [Abstract] [Full Text] [Related]
8. Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1/pd-l1 blockade in the clinical spectrum of lung cancer.
Li Y; Sharma A; Schmidt-Wolf IGH
Mol Cancer; 2024 Apr; 23(1):80. PubMed ID: 38659003
[TBL] [Abstract] [Full Text] [Related]
9. Analysis of cancer-associated fibroblasts related genes identifies COL11A1 associated with lung adenocarcinoma prognosis.
Zheng H; Tan J; Qin F; Zheng Y; Yang X; Qin X; Liao H
BMC Med Genomics; 2024 Apr; 17(1):97. PubMed ID: 38649961
[TBL] [Abstract] [Full Text] [Related]
10. First-line treatment Patterns and Outcomes in Advanced Non-Small Cell lung cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy.
Wagenius G; Vikström A; Berglund A; Salomonsson S; Bencina G; Hu X; Chirovsky D; Brunnström H
Acta Oncol; 2024 Apr; 63():198-205. PubMed ID: 38643377
[TBL] [Abstract] [Full Text] [Related]
11. Phase 1a dose escalation study of ivonescimab (AK112/SMT112), an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors.
Frentzas S; Austria Mislang AR; Lemech C; Nagrial A; Underhill C; Wang W; Wang ZM; Li B; Xia Y; Coward JIG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38642937
[TBL] [Abstract] [Full Text] [Related]
12. Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer.
Zheng L; Hu F; Huang L; Lu J; Yang X; Xu J; Wang S; Shen Y; Zhong R; Chu T; Zhang W; Li Y; Zheng X; Han B; Zhong H; Nie W; Zhang X
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38641349
[TBL] [Abstract] [Full Text] [Related]
13. Soluble programmed death ligand 1 as prognostic biomarker in non-small cell lung cancer patients receiving nivolumab, pembrolizumab or atezolizumab therapy.
Brun SS; Hansen TF; Wen SWC; Nyhus CH; Bertelsen L; Jakobsen A; Hansen TS; Nederby L
Sci Rep; 2024 Apr; 14(1):8993. PubMed ID: 38637655
[TBL] [Abstract] [Full Text] [Related]
14. Effect of the STK11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
15. Neoadjuvant Chemo-Immunotherapy for Early-Stage Non-Small Cell lung cancer: A Systematic Review and Meta-Analysis.
Banna GL; Hassan MA; Signori A; Giunta EF; Maniam A; Anpalakhan S; Acharige S; Ghose A; Addeo A
JAMA Netw Open; 2024 Apr; 7(4):e246837. PubMed ID: 38625698
[TBL] [Abstract] [Full Text] [Related]
16. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and pd-l1 enhances antitumor responses.
Tapia-Galisteo A; Sánchez-Rodríguez I; Narbona J; Iglesias-Hernández P; Aragón-García S; Jiménez-Reinoso A; Compte M; Khan S; Tsuda T; Chames P; Lacadena J; Álvarez-Vallina L; Sanz L
Oncoimmunology; 2024; 13(1):2338558. PubMed ID: 38623463
[TBL] [Abstract] [Full Text] [Related]
17. Real-world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study.
Lee J; Ahn HK; Kim SW; Han JY; Lee SS; Park HS; Lee HW; Kim JH; Cho E; Huggenberger R; Cho BC
Cancer Med; 2024 Apr; 13(7):e7174. PubMed ID: 38622869
[TBL] [Abstract] [Full Text] [Related]
18. T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC.
Yi L; Xu Z; Ma T; Wang C; Wei P; Xiao B; Zhang H; Che N; Liu Z; Han Y
Cancer Immunol Immunother; 2024 Apr; 73(6):99. PubMed ID: 38619623
[TBL] [Abstract] [Full Text] [Related]
19. Iridium(III)-Based pd-l1 Agonist Regulates p62 and ATF3 for Enhanced cancer Immunotherapy.
Deng D; Wang M; Su Y; Fang H; Chen Y; Su Z
J Med Chem; 2024 Apr; 67(8):6810-6821. PubMed ID: 38613772
[TBL] [Abstract] [Full Text] [Related]
20. Predictive Value of NLR and PLR in Driver-Gene-Negative Advanced Non-Small Cell lung cancer Treated with PD-1/pd-l1 Inhibitors: A Single Institutional Cohort Study.
Yuan Q; Xu C; Wang W; Zhang Q
Technol Cancer Res Treat; 2024; 23():15330338241246651. PubMed ID: 38613344
[TBL] [Abstract] [Full Text] [Related]
[Next]
